Icatibant Universal Farma

Icatibant, the active ingredient in Icatibant Universal Farma, is a bradykinin B2 receptor antagonist presented as a subcutaneous injectable formulation for injection use. It is employed to treat acute hereditary angioedema attacks in patients with confirmed HAE type I or II, providing rapid relief of swelling and associated pain.

GNH USA supplies Icatibant Universal Farma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable cold‑chain logistics for injectable biologics. Our distribution network spans Europe, Asia, Africa and the Americas, ensuring timely access to this essential therapy.

Icatibant is used to manage bradykinin‑mediated hereditary angioedema attacks, providing rapid symptom control.

- Hereditary angioedema attacks: reduces swelling and pain during acute episodes. - Hereditary angioedema type I: provides rapid relief of airway and peripheral edema. - Hereditary angioedema type II: blocks bradykinin effects to prevent progression of attacks.

Icatibant may cause a range of adverse reactions following subcutaneous administration.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Erythema: localized redness around the injection area. - Nausea: occasional feeling of queasiness. - Headache: transient mild headache.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Severe hypersensitivity reactions: including angioedema at sites other than the injection area. - Hypotension: sudden drop in blood pressure that may cause dizziness or fainting.

Before using Icatibant, consider the following safety measures.

- Pregnancy: safety not established; use only if potential benefit justifies the risk. - Breastfeeding: unknown effects; weigh benefits against possible risks. - Renal impairment: no dosage adjustment required, but monitor for adverse events. - Concomitant ACE inhibitors: may increase bradykinin levels; monitor closely. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that affect bradykinin pathways or hemodynamics.

Major Interactions (Avoid): - ACE inhibitors: may elevate bradykinin levels, increasing risk of angioedema. - Estrogen‑containing contraceptives: can potentiate bradykinin‑mediated swelling. - Other bradykinin B2 antagonists: additive pharmacologic effect may lead to excessive blockade.

Moderate Interactions (Monitor Closely): - NSAIDs: may exacerbate gastrointestinal irritation. - Diuretics: could influence fluid balance and blood pressure. - Corticosteroids: may alter immune response and affect infection risk.